Literature DB >> 8321831

Nasal insulin delivery with dimethyl-beta-cyclodextrin as an absorption enhancer in rabbits: powder more effective than liquid formulations.

N G Schipper1, S G Romeijn, J C Verhoef, F W Merkus.   

Abstract

The nasal absorption of insulin using dimethyl-beta-cyclodextrin (DM beta CD) as an absorption enhancer in rabbits was studied. The nasal administration of insulin/DM beta CD liquid formulations did not result in significant changes in serum insulin and blood glucose concentrations. In contrast, previous experiments in rats showed that the addition of DM beta CD to the liquid nasal formulation resulted in an almost-complete insulin absorption, with a concomitant strong hypoglycaemic response. Apparently, the effect of the cyclodextrin derivative on insulin absorption differs between animal species following nasal delivery of insulin/DM beta CD solutions. On the other hand, nasal administration of the lyophilized insulin/DM beta CD powder dosage form in rabbits resulted in increased serum insulin concentrations, and a maximum decrease in blood glucose of about 50%. The absolute bioavailability of the nasally administered insulin/DM beta CD powder was 13 +/- 4%, compared to 1 +/- 1% for both an insulin/DM beta CD liquid and an insulin/lactose powder formulation. It is concluded that insulin powder formulations with DM beta CD as an absorption enhancer are much more effective than liquid formulations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8321831     DOI: 10.1023/a:1018999414088

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  11 in total

Review 1.  Absorption of peptides and proteins from the respiratory tract and the potential for development of locally administered vaccine.

Authors:  D T O'Hagan; L Illum
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1990       Impact factor: 4.889

2.  Interspecies differences in the nasal absorption of insulin.

Authors:  F W Merkus; J C Verhoef; S G Romeijn; N G Schipper
Journal:  Pharm Res       Date:  1991-10       Impact factor: 4.200

3.  Intranasal bioavailability of insulin powder formulations: effect of permeation enhancer-to-protein ratio.

Authors:  W A Lee; B A Narog; T W Patapoff; Y J Wang
Journal:  J Pharm Sci       Date:  1991-08       Impact factor: 3.534

4.  Effects of absorption enhancers on human nasal tissue ciliary movement in vitro.

Authors:  W A Hermens; P M Hooymans; J C Verhoef; F W Merkus
Journal:  Pharm Res       Date:  1990-02       Impact factor: 4.200

5.  Nasal administration of glucagon and human calcitonin to healthy subjects: a comparison of powders and spray solutions and of different enhancing agents.

Authors:  A E Pontiroli; M Alberetto; A Calderara; E Pajetta; G Pozza
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

6.  Intranasal administration of peptides: nasal deposition, biological response, and absorption of desmopressin.

Authors:  A S Harris; I M Nilsson; Z G Wagner; U Alkner
Journal:  J Pharm Sci       Date:  1986-11       Impact factor: 3.534

7.  The effects of permeation enhancers on the surface morphology of the rat nasal mucosa: a scanning electron microscopy study.

Authors:  R D Ennis; L Borden; W A Lee
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

8.  Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats.

Authors:  F W Merkus; J C Verhoef; S G Romeijn; N G Schipper
Journal:  Pharm Res       Date:  1991-05       Impact factor: 4.200

9.  Insulin administered intranasally as an insulin-bile salt aerosol. Effectiveness and reproducibility in normal and diabetic subjects.

Authors:  A C Moses; G S Gordon; M C Carey; J S Flier
Journal:  Diabetes       Date:  1983-11       Impact factor: 9.461

Review 10.  Comparative aspects of nasal airway anatomy: relevance to inhalation toxicology.

Authors:  J R Harkema
Journal:  Toxicol Pathol       Date:  1991       Impact factor: 1.902

View more
  10 in total

Review 1.  Absorption enhancers for nasal drug delivery.

Authors:  Stanley S Davis; Lisbeth Illum
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Delivery of nasal powders of beta-cyclodextrin by insufflation.

Authors:  A De Ascentiis; R Bettini; G Caponetti; P L Catellani; M T Peracchia; P Santi; P Colombo
Journal:  Pharm Res       Date:  1996-05       Impact factor: 4.200

3.  Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers.

Authors:  M R Lofwall; D E Moody; W B Fang; P A Nuzzo; S L Walsh
Journal:  J Clin Pharmacol       Date:  2011-05-24       Impact factor: 3.126

4.  The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.

Authors:  Lisa S Middleton; Paul A Nuzzo; Michelle R Lofwall; David E Moody; Sharon L Walsh
Journal:  Addiction       Date:  2011-05-03       Impact factor: 6.526

5.  Insoluble powder formulation as an effective nasal drug delivery system.

Authors:  Fusashi Ishikawa; Mika Murano; Minoru Hiraishi; Toshikazu Yamaguchi; Ikumi Tamai; Akira Tsuji
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

6.  Nasal administration of an ACTH(4-9) peptide analogue with dimethyl-beta-cyclodextrin as an absorption enhancer: pharmacokinetics and dynamics.

Authors:  N G Schipper; J C Verhoef; L M De Lannoy; S G Romeijn; J H Brakkee; V M Wiegant; W H Gispen; F W Merkus
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

7.  The effect of cyclodextrins on the stability of peptides in nasal enzymic systems.

Authors:  W J Irwin; A K Dwivedi; P A Holbrook; M J Dey
Journal:  Pharm Res       Date:  1994-12       Impact factor: 4.200

8.  Cyclodextrins as mucosal absorption promoters of insulin. II. Effects of beta-cyclodextrin derivatives on alpha-chymotryptic degradation and enteral absorption of insulin in rats.

Authors:  Z Shao; Y Li; T Chermak; A K Mitra
Journal:  Pharm Res       Date:  1994-08       Impact factor: 4.200

9.  Drug delivery studies in Caco-2 monolayers. IV. Absorption enhancer effects of cyclodextrins.

Authors:  L Hovgaard; H Brøndsted
Journal:  Pharm Res       Date:  1995-09       Impact factor: 4.200

10.  Tablets of "Hydrochlorothiazide in Cyclodextrin in Nanoclay": A New Nanohybrid System with Enhanced Dissolution Properties.

Authors:  Francesca Maestrelli; Marzia Cirri; Fátima García-Villén; Ana Borrego-Sánchez; César Viseras Iborra; Paola Mura
Journal:  Pharmaceutics       Date:  2020-01-28       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.